Caribou Biosciences CRBU 深 沪
已收盘 08-08 16:00:00 美东时间
1.73
-0.080
-4.42%
华盛通- 最 高1.87
- 今 开1.86
- 成交量 65.87万股
- 最 低 1.715
- 昨 收 1.81
- 总市值 1.61亿
- 52周最高 2.9995
- 市盈率 静 --
- 换手率 0.71%
- 52周最低 0.66
- 委 比 87.16%
- 总股本 9300.46万
- 历史最高 32.645
- 量 比 0.55
- 振 幅 8.56%
- 历史最低 0.66
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Caribou Biosciences Regains Nasdaq Compliance
Caribou Biosciences ( ($CRBU) ) just unveiled an update. On June 18, 2025, Cari...
06-24 02:41
Caribou Biosciences Confirms Director Elections and Auditor
The latest announcement is out from Caribou Biosciences ( ($CRBU) ). On June 12...
06-14 04:50
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference
Caribou Biosciences, Inc., a CRISPR genome-editing company, announced that its CEO, Rachel Haurwitz, PhD, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT. For more information and to access the webcast, visit the Events page on Caribou’s website, where webcasts will be available for at least 30 days post-event.
05-28 20:00
艾伯维挥起拳头
转自：新康界 艾伯维，作为昔日药王的拥有者，面临专利悬崖压境，举起拳头挥向新战场！ 自免领域并购提速、神经科学重金押注、ADC赛道连出重拳，艾伯维以一场战略大突...
05-25 10:59
Caribou Biosciences Q1 EPS $(0.43) Beats $(0.44) Estimate, Sales $2.35M Beat $1.75M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.44) by 2.27 percent. This is a 6.52 percent increase over losses of $(0.46) per share from
05-09 04:50
美股大行评级 | Compass Point：上调Affirm Holdings评级至"买入"，目标价从61美元升至64美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1109399410911752193.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Femasys Inc Ordinary Shares(FEMY)"买入"评级，目标价从12美元升至15美元</p> <p>• HC Wainwright & C
03-20 09:49
Caribou Biosciences Advances CRISPR Therapies Amid Financial Challenges
Caribou Biosciences, Inc. ( ($CRBU) ) has released its Q4 earnings. Here is a b...
03-12 12:09
Caribou Biosciences Q4 2024 GAAP EPS $(0.39) Beats $(0.42) Estimate, Sales $2.08M Miss $2.11M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.42) by 7.14 percent. This is unchanged from the same period last year. The company
03-11 04:12
CRBU Lawsuit Alert! Class Action Against Caribou Biosciences Inc.
Aclass actionlawsuit was filed against Caribou Biosciences Inc. ($C...
02-18 20:13
美股大行评级 | 潜在涨幅297%！SLDB获机构首予“买入”评级，目标价16美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1084034232603127809.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• TD Cowen：上调GeneDx目标价从75美元至118美元</p> <p>• HC Wainwright & Co.：维持Sana Biotechnology(SANA)"买入"评级，目标价从8美元升至11美元
01-09 09:31
